Elucidating the Role of MicroRNA-18a in Propelling a Hybrid Epithelial-Mesenchymal Phenotype and Driving Malignant Progression in ER-Negative Breast Cancer

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2024 May 24

PMID 38786043

Authors

Madhumathy G Nair

Apoorva D Mavatkar

Chandrakala M Naidu

Snijesh V P

Anupama C E

Savitha Rajarajan

Sarthak Sahoo

Gayathri Mohan

Vishnu Sunil Jaikumar

Rakesh S Ramesh

Srinath B S

Mohit Kumar Jolly

Tessy Thomas Maliekal

Jyothi S Prabhu

Affiliations

Soon will be listed here.

Abstract

Epigenetic alterations that lead to differential expression of microRNAs (miRNAs/miR) are known to regulate tumour cell states, epithelial-mesenchymal transition (EMT) and the progression to metastasis in breast cancer. This study explores the key contribution of miRNA-18a in mediating a hybrid E/M cell state that is pivotal to the malignant transformation and tumour progression in the aggressive ER-negative subtype of breast cancer. The expression status and associated effects of miR-18a were evaluated in patient-derived breast tumour samples in combination with gene expression data from public datasets, and further validated in in vitro and in vivo breast cancer model systems. The clinical relevance of the study findings was corroborated against human breast tumour specimens (n = 446 patients). The down-regulated expression of miR-18a observed in ER-negative tumours was found to drive the enrichment of hybrid epithelial/mesenchymal (E/M) cells with luminal attributes, enhanced traits of migration, stemness, drug-resistance and immunosuppression. Further analysis of the miR-18a targets highlighted possible hypoxia-inducible factor 1-alpha (HIF-1α)-mediated signalling in these tumours. This is a foremost report that validates the dual role of miR-18a in breast cancer that is subtype-specific based on hormone receptor expression. The study also features a novel association of low miR-18a levels and subsequent enrichment of hybrid E/M cells, increased migration and stemness in a subgroup of ER-negative tumours that may be attributed to HIF-1α mediated signalling. The results highlight the possibility of stratifying the ER-negative disease into clinically relevant groups by analysing miRNA signatures.

References

Hu Y, Smyth G . ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009; 347(1-2):70-8. DOI: 10.1016/j.jim.2009.06.008. View

Putti T, Abd El-Rehim D, Rakha E, Paish C, Lee A, Pinder S . Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol. 2004; 18(1):26-35. DOI: 10.1038/modpathol.3800255. View

Kroger C, Afeyan A, Mraz J, Eaton E, Reinhardt F, Khodor Y . Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells. Proc Natl Acad Sci U S A. 2019; 116(15):7353-7362. PMC: 6462070. DOI: 10.1073/pnas.1812876116. View

Kolenda T, Guglas K, Kopczynska M, Sobocinska J, Teresiak A, Blizniak R . Good or not good: Role of miR-18a in cancer biology. Rep Pract Oncol Radiother. 2020; 25(5):808-819. PMC: 7451592. DOI: 10.1016/j.rpor.2020.07.006. View

Wahba H, El-Hadaad H . Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015; 12(2):106-16. PMC: 4493381. DOI: 10.7497/j.issn.2095-3941.2015.0030. View

Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74. PMC: 58566. DOI: 10.1073/pnas.191367098. View

Nair M, D A, M C, Vp S, Patil S, Ce A . miR-18a Mediates Immune Evasion in ER-Positive Breast Cancer through Wnt Signaling. Cells. 2022; 11(10). PMC: 9139289. DOI: 10.3390/cells11101672. View

Turashvili G, Brogi E . Tumor Heterogeneity in Breast Cancer. Front Med (Lausanne). 2017; 4:227. PMC: 5727049. DOI: 10.3389/fmed.2017.00227. View

Prabhu J, Korlimarla A, Anupama C, Alexander A, Raghavan R, Kaul R . Dissecting the Biological Heterogeneity within Hormone Receptor Positive HER2 Negative Breast Cancer by Gene Expression Markers Identifies Indolent Tumors within Late Stage Disease. Transl Oncol. 2017; 10(4):699-706. PMC: 5506875. DOI: 10.1016/j.tranon.2017.04.011. View

10.

Zhang Q, Qiao L, Liao J, Liu Q, Liu P, Liu L . A novel hypoxia gene signature indicates prognosis and immune microenvironments characters in patients with hepatocellular carcinoma. J Cell Mol Med. 2021; 25(8):3772-3784. PMC: 8051726. DOI: 10.1111/jcmm.16249. View

11.

Freeberg M, Fromont L, DAltri T, Romero A, Ciges J, Jene A . The European Genome-phenome Archive in 2021. Nucleic Acids Res. 2021; 50(D1):D980-D987. PMC: 8728218. DOI: 10.1093/nar/gkab1059. View

12.

Nair M, Prabhu J, Korlimarla A, Rajarajan S, P S H, Kaul R . miR-18a activates Wnt pathway in ER-positive breast cancer and is associated with poor prognosis. Cancer Med. 2020; 9(15):5587-5597. PMC: 7402845. DOI: 10.1002/cam4.3183. View

13.

Duvivier L, Gerard L, Diaz A, Gillet J . Linking ABC transporters to the hallmarks of cancer. Trends Cancer. 2023; 10(2):124-134. DOI: 10.1016/j.trecan.2023.09.013. View

14.

Pommier R, Sanlaville A, Tonon L, Kielbassa J, Thomas E, Ferrari A . Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution. Nat Commun. 2020; 11(1):3431. PMC: 7347884. DOI: 10.1038/s41467-020-17249-7. View

15.

Hou J, Ye X, Wang Y, Li C . Stratification of Estrogen Receptor-Negative Breast Cancer Patients by Integrating the Somatic Mutations and Transcriptomic Data. Front Genet. 2021; 12:610087. PMC: 7886807. DOI: 10.3389/fgene.2021.610087. View

16.

Groger C, Grubinger M, Waldhor T, Vierlinger K, Mikulits W . Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS One. 2012; 7(12):e51136. PMC: 3519484. DOI: 10.1371/journal.pone.0051136. View

17.

Xu L, Yu W, Xiao H, Lin K . BIRC5 is a prognostic biomarker associated with tumor immune cell infiltration. Sci Rep. 2021; 11(1):390. PMC: 7801710. DOI: 10.1038/s41598-020-79736-7. View

18.

Krutilina R, Sun W, Sethuraman A, Brown M, Seagroves T, Pfeffer L . MicroRNA-18a inhibits hypoxia-inducible factor 1α activity and lung metastasis in basal breast cancers. Breast Cancer Res. 2014; 16(4):R78. PMC: 4405876. DOI: 10.1186/bcr3693. View

19.

Nair M, Desai K, Prabhu J, Hari P, Remacle J, Sridhar T . β3 integrin promotes chemoresistance to epirubicin in MDA-MB-231 through repression of the pro-apoptotic protein, BAD. Exp Cell Res. 2016; 346(1):137-45. DOI: 10.1016/j.yexcr.2016.05.015. View

20.

Hong H, Chuang C, Huang W, Weng S, Chen C, Chang K . A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse. Theranostics. 2020; 10(19):8771-8789. PMC: 7392022. DOI: 10.7150/thno.46142. View